Monday in Whitewater will be sunny with a high of 86. Sunrise is 5:15 AM and sunset 8:35 PM, for 15h 19m 19s of daytime. The moon is a waxing crescent with 14.8% of its visible disk illuminated.
Recommended for reading in full —
Austin Fast reports Rural Communities Fall Further Behind In COVID-19 Vaccination Rates:
A second CDC report from early June sheds light on the demographic and social factors linked to lower vaccination rates among all counties, whether rural or urban.
The CDC ranks over 3,000 counties nationwide using a social vulnerability index that measures 15 factors such as poverty, poor transit and crowded housing that weaken a community’s capacity to respond to disaster.
Researchers divided counties into four categories — large urban, suburban, small-to-medium urban, and rural — and looked for which demographic profiles were linked to lower vaccination rates. Across all these categories, households with children, people living with disabilities and single-parent households were more likely to see lower vaccination rates. And researchers say these gaps are particularly pronounced in suburban and rural counties.
Counties with higher numbers of mobile home residents, as well as those with higher poverty and lower education rates, also lagged significantly behind other counties within their rural-urban category, according to the CDC report.
“Rural communities often have a higher proportion of residents over 65 years of age, lacking health insurance, living with underlying medical conditions or disabilities, and with limited access to health care facilities with intensive care capabilities, which may make them more likely to get sick or die from COVID-19,” says Vaughn Barry, a CDC epidemiologist and one of the report’s lead authors.
Carl Zimmer reports Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine:
Novavax, a small American company buoyed by lavish support from the U.S. government, announced on Monday the results of a clinical trial of its Covid-19 vaccine in the United States and Mexico, finding that its two-shot inoculation provides potent protection against the coronavirus.
In the 29,960-person trial, the vaccine demonstrated an overall efficacy of 90.4 percent, on par with the vaccines made by Pfizer-BioNTech and Moderna, and higher than the one-shot vaccine from Johnson & Johnson. The Novavax vaccine showed an efficacy of 100 percent at preventing moderate or severe disease.
Despite these impressive results, the vaccine’s future in the United States is uncertain and it might be needed more in other countries. Novavax says it may not seek emergency authorization from the Food and Drug Administration until the end of September. And with a plentiful supply of three other authorized vaccines, it’s possible that the agency may tell Novavax to apply instead for a full license — a process that could require several extra months.
Victoria Bekiempis reports Legal storm clouds gather over Donald Trump’s future:
The most threatening legal investigation, which involves potential for jail either for Trump or his associates if it proceeded and resulted in conviction, does not relate to his presidential duties.
The Washington Post reported on 25 May that Manhattan prosecutors had convened the grand jury that is “expected to decide whether to indict Donald Trump, other executives at his company or the business itself, should prosecutors present the panel with criminal charges”.
This development suggests that Manhattan prosecutors’ inquiry into Trump and his business concerns has hit an “advanced stage” after proceeding for more than two years. More, it indicates that Manhattan prosecutors believe they have discovered evidence of a crime. This potential evidence could be against Trump, an executive at his company, or his business.